EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds : vimarsana.com

On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC). The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide. These were previously filed as provisional pate

Related Keywords

Israel , India , United States , China , Gerd Altman , Adi Zuloff Shani , Nasdaq , Trademark Office , Scisparc Ltd , Ministry Of Health Israel , Clearmind Medicine Inc , Patent Cooperation Treaty , United States Patent , Clearmind Medicine , Stock Market Game , Benzinga Pro , Day Trial , Ibogaine And Ketamine Compounds , Learmind , Atent Applications , Learmind Medicine , Lcohol Use Disorder ,